---
title: "Glaukos Corporation (GKOS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GKOS.US.md"
symbol: "GKOS.US"
name: "Glaukos Corporation"
industry: "Health Care Equipment"
datetime: "2026-03-14T04:11:58.585Z"
locales:
  - [en](https://longbridge.com/en/quote/GKOS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GKOS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GKOS.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/GKOS.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/GKOS.US.md)


# Glaukos Corporation (GKOS.US)

## Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.glaukos.com](https://www.glaukos.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:16.000Z

**Overall: C (0.44)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 46 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 32.33% |  |
| Net Profit YoY | -28.23% |  |
| P/B Ratio | 8.65 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5676788905.48 |  |
| Revenue | 507442000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -26.38% | E |
| Profit Margin | -36.99% | E |
| Gross Margin | 77.97% | A |
| Revenue YoY | 32.33% | A |
| Net Profit YoY | -28.23% | D |
| Total Assets YoY | -8.34% | E |
| Net Assets YoY | -14.44% | E |
| Cash Flow Margin | -270.36% | D |
| OCF YoY | 32.33% | A |
| Turnover | 0.54 | C |
| Gearing Ratio | 26.56% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Glaukos Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "32.33%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-28.23%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.65",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5676788905.48",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "507442000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-26.38%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-36.99%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "77.97%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "32.33%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-28.23%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.34%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-14.44%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-270.36%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "32.33%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.56%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -30.01 | 163/188 | - | - | - |
| PB | 8.58 | 115/188 | 8.39 | 7.18 | 6.55 |
| PS (TTM) | 11.10 | 121/188 | 14.12 | 13.30 | 11.57 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Abbott Laboratories (ABT.US) | B | C | C | C | C | B |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | B | B | C | B | B |
| 05 | Boston Scientific (BSX.US) | B | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-11T04:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 73% |
| Overweight | 3 | 20% |
| Sell | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 97.02 |
| Highest Target | 165.00 |
| Lowest Target | 72.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GKOS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GKOS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GKOS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GKOS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**